Hypoxoside

Hypoxoside is a phenylheptenyl glucoside extracted primarily from the African potato (Hypoxis hemerocallidea), where it acts as a biologically inactive prodrug converted in vivo to the active aglycone rooperol via beta-glucosidase activity. Rooperol then exerts antioxidant, antimutagenic, and selective cytotoxic effects through catechol-mediated free radical scavenging and interference with cellular proliferation pathways.

Origin & History

Hypoxoside is a pentenyne glycoside isolated from the African potato plant (Hypoxis hemerocallidea), native to southern Africa. It is extracted from plant materials using chromatography on Sephadex LH-20 with methanol-water (1:1) and contains two glucose units attached to benzene rings in a pentenyne skeleton.

Historical & Cultural Context

Hypoxis hemerocallidea (African potato) has been used in southern African traditional medicine, though specific historical applications of hypoxoside are not documented. The plant is recognized in chemical-historical reviews of African medicinal plants.

Health Benefits

• Antimicrobial activity against E. coli and S. enterica (preliminary in vitro evidence only)
• Selective cytotoxicity to glioblastoma cells U87 and U251 (preliminary in vitro evidence only)
• Antimutagenic properties (preliminary in vitro evidence only)
• Low toxicity profile based on preliminary tests (in vitro evidence only)
• Potential antioxidant activity through its metabolite rooperol (preliminary evidence only)

How It Works

Hypoxoside is hydrolyzed by intestinal or microbial beta-glucosidase enzymes into rooperol, a dihydroxyphenylheptenol catechol compound that functions as the pharmacologically active moiety. Rooperol scavenges reactive oxygen species via its catechol hydroxyl groups and has been observed to inhibit lipoxygenase and cyclooxygenase pathways, reducing pro-inflammatory eicosanoid synthesis. In glioblastoma cell lines U87 and U251, rooperol appears to selectively induce cytotoxicity, potentially through interference with tubulin polymerization and disruption of mitotic spindle assembly, though the precise receptor targets remain under investigation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for hypoxoside were found in the research. Current evidence is limited to in vitro studies showing antimicrobial and anticancer properties when used in silver nanoparticle synthesis.

Clinical Summary

The evidence base for hypoxoside is limited almost entirely to in vitro and animal studies, with no large-scale randomized controlled trials in humans published to date. In vitro assays demonstrated antimicrobial activity against gram-negative pathogens including Escherichia coli and Salmonella enterica, and antimutagenic effects in Ames test models, though these findings have not been validated in human clinical settings. Selective cytotoxicity against glioblastoma cell lines U87 and U251 was observed at specific rooperol concentrations in cell culture, representing preliminary proof-of-concept data only. Toxicological screening in animal models suggests a low acute toxicity profile, but human pharmacokinetic and efficacy data are currently insufficient to support therapeutic dosing recommendations.

Nutritional Profile

Hypoxoside is a norlignan diglucoside (chemical formula C₃₀H₃₈O₁₄, molecular weight ~626.6 g/mol) and is not a nutrient per se but rather a bioactive phytochemical primarily found in the corm of Hypoxis hemerocallidea (African potato). It is classified as a rooperol diglucoside, meaning it consists of the aglycone rooperol (a catechol derivative) bound to two glucose molecules. Key bioactive characteristics: The parent compound hypoxoside itself is considered a prodrug; it is converted by β-glucosidase enzymes (present in the gastrointestinal tract and released by certain cells, including activated immune cells and some tumor cells) into its biologically active aglycone, rooperol (C₁₈H₁₈O₆, MW ~330.3 g/mol). Rooperol is a dicatechol with significant antioxidant capacity due to its multiple phenolic hydroxyl groups. Approximate concentration in source material: Hypoxoside constitutes approximately 3.5–4.5% (w/w) of dried Hypoxis hemerocallidea corm, with some reports citing up to 6% depending on harvest conditions, geographic origin, and extraction methods. Typical standardized extracts may contain 2.5–4% hypoxoside. Bioavailability notes: Oral bioavailability of hypoxoside is moderate; the intact diglucoside is absorbed from the gastrointestinal tract and can be detected in serum. Conversion to rooperol occurs both in the gut lumen (via microbial β-glucosidases) and at target tissues. Phase II metabolism of rooperol produces sulfate and glucuronide conjugates (rooperol di-sulfate, rooperol sulfate-glucuronide, rooperol di-glucuronide), which circulate in plasma and are renally excreted. In clinical pharmacokinetic studies (oral doses of 1,200–3,200 mg crude extract), peak plasma levels of hypoxoside and rooperol metabolites were reached within 2–4 hours. The aglycone rooperol has higher biological activity than the parent glycoside but also higher susceptibility to first-pass metabolism. No significant macronutrient content (protein, fat, carbohydrate, fiber) is attributed to hypoxoside as an isolated compound. It contains no vitamins or minerals. Co-occurring compounds in Hypoxis corm extracts include other norlignan glycosides (dehydroxyhypoxoside, bis-dehydroxyhypoxoside), phytosterols (notably β-sitosterol and stigmasterol), stanols, and trace minerals from the plant matrix, but these are distinct from hypoxoside itself.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are absent. Hypoxoside content in Hypoxis hemerocallidea reaches up to 4.5%. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other polyphenols, antioxidants, immune-supporting botanicals, African medicinal plants

Safety & Interactions

Hypoxoside from African potato (Hypoxis hemerocallidea) preparations has raised safety concerns in HIV-positive populations, where widespread traditional use in South Africa has been associated in some reports with potential interference with antiretroviral drug metabolism, possibly through modulation of CYP3A4 and P-glycoprotein activity by rooperol. High-dose African potato extracts have been linked in case reports to pancytopenia, though it is unclear whether hypoxoside specifically or other phytoconstituents are responsible. Use during pregnancy and lactation is not recommended due to the complete absence of safety data in these populations. Individuals on immunosuppressive medications, chemotherapeutics, or anticoagulants should avoid hypoxoside supplementation until drug interaction studies are conducted.